RNAi therapeutics: companies, startups and research

Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals Inc., Novartis and GSK GlaxoSmithKline are among the corporate RNAi developers in FACTS. Alnylam and Novartis develop or commercialize GalNAc-conjugated medicines, while Arrowhead works on chemically modified siRNA. In September 2026, Arrowhead reported interim data for its dual-function candidate ARO-DIMER-PA.

FACTS identifies 8 startups, including Vir Biotechnology Inc., Empirico and Frontier Biotechnologies. Their work includes siRNA approaches for hepatitis B and patented oligonucleotide candidates. In February 2026, Frontier Biotechnologies entered a licensing agreement with GSK for two siRNA pipeline products. These examples indicate activity, not a ranking of commercial prospects.

Sun Yat Sen University, Southern Medical University and Fudan University are prominent research organizations in FACTS, with 841, 820 and 736 publications respectively in their listed records. Their work includes GalNAc-siRNA for liver targets, targeted delivery and disease models. These publication counts indicate research activity, not clinical maturity or product success.

FACTS records $213.3 million across 231 grants since 2020. It also lists 21 funding rounds totaling $111.1 billion, but that aggregate includes entries that appear unrelated to RNAi-specific development. Treat the round total cautiously; it is not a reliable standalone measure of capital invested in RNAi therapeutics.

Arrowhead Pharmaceuticals Inc. leads the listed patent holders with 46 patents, followed by Alnylam Pharmaceuticals with 22 and Regeneron Pharmaceuticals Inc. with 21. Other listed holders include the French Institute of Health and Medical Research and the University of Massachusetts, each with 17. These counts reflect the patent-holder data in FACTS.

FACTS lists 2,060 patents in its 24-month window, while its patent-growth metric is down 49.7% for the latest 12 months versus the previous 12 months. The direction is a contraction in recent patenting, not a measure of the field’s overall scientific or commercial value. Publications were down 1.6% over the same comparison.

Arrowhead Pharmaceuticals reported interim ARO-DIMER-PA results in September 2026, with reductions in PCSK9 and APOC3 from a dual-function RNAi molecule. Undecimal Bio launched in October 2026 with $18 million in seed financing focused on the siRNA “liver trap.” Recent research also examines polymer conjugates for colon-cancer delivery and GalNAc-siRNA clearance pathways.

The main approaches in FACTS are chemically modified siRNA, GalNAc conjugates, lipid nanoparticle delivery, other targeted delivery, vector-expressed shRNA and miRNA therapeutics. Chemical modification aims to improve stability; GalNAc supports liver targeting; and nanoparticles package RNA for delivery. Alternative carriers seek other tissues, while shRNA vectors and miRNA approaches introduce distinct control and specificity challenges.

FACTS identifies oncology (10,212 documents), ocular and neurological disease (3,600), liver and metabolic disease (3,450), cardiovascular disease (3,219), infectious disease (2,764) and rare genetic disorders (1,578). These figures show the range of documented application areas. GalNAc delivery is associated with liver targets, while delivery outside the liver remains an important technical challenge.

China leads the listed countries with 148,509 documents, followed by the United States with 70,428. Japan and the United Kingdom follow, with 16,113 and 16,092 documents respectively. These figures describe the distribution of documents in FACTS, rather than a direct comparison of commercial output, clinical success or manufacturing capacity.